Clinical Trial Update: Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and immunogenicity of V116 in pneumococcal vaccine-naïve adults aged 50 and older has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• V116

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-10-31